Arndt Vogel, MD

Medizinische Hochschule Hannover
Hannover, Germany

Arndt Vogel, MD, is managing senior consultant and professor in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School. He is head of the GI-Cancer Center and of the center for personalized medicine at Medical School Hannover.
Prof. Vogel’s scientific focus is the translational and clinical research in gastrointestinal cancer. Since 2004, he is leading a basic research group interested in the pathogenesis of GI-cancers with a special focus on hepatobiliary cancers and precision medicine. Arndt Vogel is a clinical investigator in oncology since 2006 and has served as principal investigator on numerous clinical trials. He is author or co-author of more than 200 articles published in peer-reviewed journals including Lancet Oncology, Cancer Cell, Gastroenterology, and Hepatology.
Prof. Vogel is member of societies including ESMO, ASCO, and EASL. He is member and chairman of Hepatobiliary Cancer Study Group of the AIO, a collaborative group in clinical oncology in Germany. Within ESMO, he is member of the ESMO Guidelines Steering Committee. Dr. Vogel has responsibilities in the establishment of the national guideline and is the coordinator of the ESMO clinical practice guideline on the management of hepatocellular carcinoma and biliary tract cancer.

Presentation(s):

• Case Study Discussion of BTC Diagnosis

  Wednesday, June 29, 2022
  11:30 – 11:45

• BTC Subtypes and Disease Heterogeneity

  Wednesday, June 29, 2022
  11:45 – 11:55

• Panel Discussion on Biomarkers in BTC

  Wednesday, June 29, 2022
  11:55 – 12:05

• Panel Discussion on Prospects for BTC Care

  Wednesday, June 29, 2022
  12:15 – 12:30

• Q&A Session

  Wednesday, June 29, 2022
  12:30 – 12:45

• O-2: Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: final results from FIGHT-202

  Wednesday, June 29, 2022
  17:27 – 17:39

• Cases With Panel Discussion: NGS as the First-line Treatment in All Patients With Advanced Bile Duct Cancer

  Wednesday, June 29, 2022
  18:10 – 18:35

• Q&A and Panel Discussion

  Wednesday, June 29, 2022
  18:35 – 18:45

• Session VII: Meet the Experts: Challenging Cases in Advanced HCC

  Thursday, June 30, 2022
  08:00 – 08:45

• Putting Targeted Therapies into Context: Impact on the Cholangiocarcinoma Treatment Landscape

  Thursday, June 30, 2022
  13:55 – 14:10

• Panel Discuss and Q&A

  Thursday, June 30, 2022
  14:10 – 14:30

• O-5: Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study

  Thursday, June 30, 2022
  15:30 – 15:42

• SO-13: Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: updated data from the open-label, phase 2 KEYNOTE-224 study

  Thursday, June 30, 2022
  15:50 – 15:58

• Cases With Panel Discussion: Management Strategy in HCC

  Thursday, June 30, 2022
  16:30 – 17:15